Cas no 4965-97-3 (Bryodulcosigenin)
Bryodulcosigenin Chemical and Physical Properties
Names and Identifiers
-
- Bryodulcosigenin
- (3S,8S,9R,10R,13R,14S,17R)-17-[(2R)-5,6-dihydroxy-6-methylheptan-2-yl]-3-hydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one
- NSC 710352
- (9β,10α)-3β,24,25-Trihydroxy-9-methyl-19-norlanost-5-en-11-one
- Bryodulocosigenin
- C08789
- (3S,8S,9R,10R,13R,14S,17R)-17-[(2R,5S)-5,6-dihydroxy-6-methylheptan-2-yl]-3-hydroxy-4,4,9,13,14-pent
- 4965-97-3
- Q27105986
- CHEBI:3198
- NS00094634
- DTXSID10331635
- AKOS040760308
- DA-51437
-
- Inchi： 1S/C30H50O4/c1-18(9-13-24(32)27(4,5)34)19-15-16-28(6)22-12-10-20-21(11-14-23(31)26(20,2)3)30(22,8)25(33)17-29(19,28)7/h10,18-19,21-24,31-32,34H,9,11-17H2,1-8H3/t18-,19-,21-,22+,23+,24?,28+,29-,30+/m1/s1
- InChI Key： FPMQKXQOBKDVHF-ZGUWQJCPSA-N
- SMILES： O=C1C[C@]2(C)[C@@H]([C@H](C)CCC(C(C)(C)O)O)CC[C@@]2(C)[C@@H]2CC=C3C(C)(C)[C@H](CC[C@H]3[C@@]21C)O
Computed Properties
- Exact Mass: 474.37100
- Monoisotopic Mass: 474.371
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 34
- Rotatable Bond Count: 5
- Complexity: 858
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 8
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 5.1
- Topological Polar Surface Area: 77.8
- Molecular Weight: 474.7
Experimental Properties
- Color/Form: Powder
- Density: 1.09±0.1 g/cm3 (20 oC 760 Torr),
- Melting Point: 186 oC (ethyl ether )
- Boiling Point: 594.9°C at 760 mmHg
- Flash Point: 327.6°C
- Refractive Index: 1.547
- Solubility: Insuluble (1.9E-3 g/L) (25 oC),
- PSA: 77.76000
- LogP: 5.67960
- Vapor Pressure: 0.0±3.8 mmHg at 25°C
Bryodulcosigenin Security Information
- Signal Word：warning
- Hazard Statement： H303 may be harmful by ingestion +h313 may be harmful by skin contact +h2413 may be harmful by inhalation
-
Warning Statement：
P264 wash thoroughly after treatment
p280 wear protective gloves / wear protective clothing / wear protective eye masks / wear protective masks
p305 if in eyes
p351 rinse carefully with water for a few minutes
p338 remove contact lenses (if any) and easy to operate, continue rinsing
p337 if eye irritation persists
p2393 get medical advice / care - Safety Instruction： H303 may be harmful by ingestion +h313 may be harmful by skin contact +h2413 may be harmful by inhalation
- Storage Condition：Please store the product under the recommended condition sin the description
Bryodulcosigenin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Chengdu Biopurify Phytochemicals Ltd | BP1851-5mg |
Bryodulcosigenin |
4965-97-3 | 98% | 5mg |
$120 | 2023-09-20 | |
| Chengdu Biopurify Phytochemicals Ltd | BP1851-20mg |
Bryodulcosigenin |
4965-97-3 | 98% | 20mg |
$296 | 2023-09-20 | |
| Chengdu Biopurify Phytochemicals Ltd | BP1851-10mg |
Bryodulcosigenin |
4965-97-3 | 98% | 10mg |
$165 | 2023-09-20 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce55362-1mg |
Bryodulcosigenin |
4965-97-3 | 98% | 1mg |
￥0.00 | 2023-09-07 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce55362-5mg |
Bryodulcosigenin |
4965-97-3 | 98% | 5mg |
￥0.00 | 2023-09-07 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN1455-1 mg |
Bryodulcosigenin |
4965-97-3 | 99.24% | 1mg |
￥1463.00 | 2022-04-26 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN1455-5 mg |
Bryodulcosigenin |
4965-97-3 | 99.24% | 5mg |
￥2987.00 | 2022-04-26 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN1455-10 mg |
Bryodulcosigenin |
4965-97-3 | 99.24% | 10mg |
￥4480.00 | 2022-04-26 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN1455-25 mg |
Bryodulcosigenin |
4965-97-3 | 99.24% | 25mg |
￥7987.00 | 2022-04-26 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN1455-50 mg |
Bryodulcosigenin |
4965-97-3 | 99.24% | 50mg |
￥12096.00 | 2022-04-26 |
Bryodulcosigenin Related Literature
-
Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
-
Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
-
Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
-
Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
Additional information on Bryodulcosigenin
Bryodulcosigenin: A Comprehensive Overview
Bryodulcosigenin, also known by its CAS number 4965-97-3, is a compound that has garnered significant attention in the scientific community due to its unique properties and potential applications. This compound is a derivative of glycyrrhetinic acid, which is commonly found in licorice roots. Recent studies have highlighted its role in various biological processes, making it a subject of interest for researchers in the fields of pharmacology, nutrition, and natural product chemistry.
The name "Bryodulcosigenin" itself is derived from its structural components, with "bryo" referring to its origin in certain plant species and " dulcosigenin" indicating its glycyrrhetinic acid backbone. This naming convention reflects the compound's natural origins and its chemical composition. Researchers have identified that Bryodulcosigenin exhibits antioxidant and anti-inflammatory properties, which are crucial for understanding its potential therapeutic applications.
In recent years, advancements in analytical techniques have allowed for a deeper understanding of Bryodulcosigenin's molecular structure and bioactivity. For instance, studies using high-resolution mass spectrometry have revealed the precise molecular formula of Bryodulcosigenin as C20H30O10. This detailed structural information has been instrumental in elucidating its pharmacokinetic properties and bioavailability.
One of the most promising areas of research involving Bryodulcosigenin is its potential as an anti-cancer agent. Preclinical studies have demonstrated that Bryodulcosigenin can induce apoptosis in various cancer cell lines while sparing normal cells, suggesting a selective cytotoxicity that could be advantageous in chemotherapy. Additionally, Bryodulcosigenin has shown synergistic effects when combined with conventional chemotherapeutic agents, enhancing their efficacy while reducing side effects.
Beyond cancer therapy, Bryodulcosigenin has also been investigated for its role in managing chronic inflammatory diseases such as arthritis and cardiovascular disorders. Its ability to modulate key inflammatory pathways, including the NF-κB and MAPK signaling pathways, underscores its potential as a novel therapeutic agent for these conditions.
The global market for natural products with bioactive properties is rapidly expanding, driven by increasing consumer demand for safer and more effective health supplements. In this context, Bryodulcosigenin stands out as a valuable ingredient due to its proven health benefits and minimal side effects compared to synthetic alternatives.
In conclusion, Bryodulcosigenin (CAS No. 4965-97-3) represents a significant advancement in the field of natural product research. With ongoing studies exploring its diverse applications in medicine and nutrition, this compound holds immense promise for future therapeutic developments.
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
